Bolt Biotherapeutics (BOLT) Return on Capital Employed (2021 - 2026)
Bolt Biotherapeutics (BOLT) posted Return on Capital Employed of 70.15% for Q1 2026, down 1.92% sequentially from 68.83% in Q4 2025, and up 1581.0% YoY from 4.17% in Q1 2025.
Bolt Biotherapeutics (BOLT) Return on Capital Employed (2021 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Return on Capital Employed for 6 years, with the latest figure at 70.15% in Q1 2026.
- Quarterly Return on Capital Employed rose 1581.0% year-over-year to 70.15% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 70.15% (up 1581.0% YoY) and the FY2025 annual result came in at 51.77%, up 1239.0% from the prior year.
- Return on Capital Employed declined to 70.15% in Q1 2026 per BOLT's latest filing, from 68.83% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 35.6% in Q1 2022 and troughed at 85.96% in Q1 2025.
- A 5-year average of 59.3% and a median of 55.62% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2026: Return on Capital Employed slumped 3063 bps in 2024, then surged 1581 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 42.3% in 2022, then declined by 22 bps to 51.79% in 2023, then slumped by 59 bps to 82.42% in 2024, then advanced by 16 bps to 68.83% in 2025, then retreated by 2 bps to 70.15% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 70.15%, 68.83%, and 76.18% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.00 Bn | 132.14 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.24 Bn | 60.06 Bn | 1.37 Bn | - |
| 4 | Moderna | 62.41 Bn | 57.27 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.18 Bn | 27.88 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.93 Bn | 10.54 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 7.88% |
| 10 | Bolt Biotherapeutics | 5.88 Mn | 5.88 Mn | - | -84.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -84.70% |
| Mar 31, 2026 | -70.15% |
| Dec 31, 2025 | -68.83% |
| Sep 30, 2025 | -76.18% |
| Jun 30, 2025 | -79.98% |
| Mar 31, 2025 | -85.96% |
| Dec 31, 2024 | -82.42% |
| Sep 30, 2024 | -76.92% |
| Jun 30, 2024 | -67.14% |
| Mar 31, 2024 | -55.62% |
| Dec 31, 2023 | -51.79% |
| Sep 30, 2023 | -47.16% |
| Jun 30, 2023 | -45.15% |
| Mar 31, 2023 | -42.27% |
| Dec 31, 2022 | -42.30% |
| Sep 30, 2022 | -42.13% |
| Jun 30, 2022 | -38.57% |
| Mar 31, 2022 | -35.60% |
| Dec 31, 2021 | -31.00% |
| Sep 30, 2021 | -26.10% |